Compugen Ltd. (CGEN)
Automate Your Wheel Strategy on CGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including CGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CGEN
- Rev/Share 0.3112
- Book/Share 0.6133
- PB 2.7882
- Debt/Equity 0.053
- CurrentRatio 5.2578
- ROIC -0.2291
- MktCap 159907230.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -10.759
- Debt/Assets 0.0253
- DivYield 0
- ROE -0.2439
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CGEN | Oppenheimer | -- | Outperform | -- | $4 | Jan. 13, 2025 |
News
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.08 per share a year ago.
Read More
Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Compugen Ltd. (NASDAQ:CGEN ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR & Corporate Communications Anat Cohen-Dayag - President & CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Daina Graybosch - Leerink Partners Rohan Mathur - Oppenheimer Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for joining us today.
Read More
Compugen Reports First Quarter 2025 Results
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to Gilead Partner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASCO Solid financial position with cash runway expected to fund operations into 2027 Key leadership transitions to take effect in September 2025 HOLON, Israel , May 19, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: …
Read More
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025: H.C.
Read More
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.11 per share a year ago.
Read More
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology and immune regulation Leveraging Compugen's computational analytical tools uncovered high consistency in single-cell expression levels across Ultima's UG 100 sequencing platform, offering a potential advantage for demarcation of transcript termination. Research presented at Advances in Genome Biology and Technology (AGBT) 2025 General Meeting HOLON, Israel , Feb. 26, 2025 /PRNewswire/ -- Compugen Ltd.
Read More
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
HOLON, Israel , Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open.
Read More
About Compugen Ltd. (CGEN)
- IPO Date 2000-08-11
- Website https://cgen.com
- Industry Biotechnology
- CEO Dr. Anat Cohen-Dayag Ph.D.
- Employees 74